Jun

· CU01 Phase 2b Results Presented at the ADA 2026

· MOU with the College of Pharmacy, Gyeongsang National University

· MOU with AIMBLE, an AI Drug Discovery Company

· MT-201 Selected for the Korea Drug Development Fund (KDDF) Program

May

· Preclinical Results of MT-103 Presented Orally at ARVO 2026

· Retinal Disease Bispecific Antibody MT-103 Licensed to Memento Medicines

Apr

· CU01 Phase 2b Clinical Trial CSR(Clinical Study Reports) received (Diabetic Nephropathy)

Feb

· Completed Merger with Active Pharmaceutical Ingredient (API) Company

Jan

· CU01 Phase 2b Topline Results Announced (Diabetic Nephropathy)

Sep
· Signed an MOU with BORYUNG, to co-develop CU01 

May
· CU06 Official International Nonproprietary Name Rivasterat Registered with WHO

Mar
· Approved the absorptive merger of Daesung Pharmtech, an API company

Jan
· CP01-R01 (Chronic Kidney Disease in Companion Animals), Phase 3 IND application approved by the APQA

Dec

· CU104 (Ulcerative Colitis), Phase 2 IND application approved in Europe

Seb

· Co-development agreement with CAND to develop treatments for kidney disease of companion animals

Jul

· Signed on MOU with STANDIGM, an artificial intelligence (AI) drug discovery company

Jun

· Signed on MOU with MabTics, an antibody therapeutics company
· CU104 (Ulcerative Colitis), Phase 2 IND application approved by the FDA

· Signed an MOU with Center for Companion Animal New drug Development (CAND)

Apr

· Signed MOU with College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University

Dec

· Acquired high-tech product certification from the Ministry of Trade, Industry and Energy

· Grand Prize at the 2022 Korea Value Management Award by HANKOOKILBO

Nov

· Acquired R&D type venture enterprise certification

Seb

· CU06 (Diabetic macular edema), Phase 2a IND application approved

· New CFO·Vice President Appointed

Jul

· CU01 (Diabetic nephropathy), Phase 2a IND application approved

Jun

· Computer-Aided drug design
· CU06, Finalized CU06 Phase1 CSR

· Poster presentation of CU01 diabetic nephropathy Phase 2a clinical trial results at 2022 American Diabetes Association (ADA) Conference

Apr

· Relocated research center and welcomed Seocho Headquarters phase

Jan

· Established 2nd bio research center

Nov

· New CEO Appointed

Oct

· CU06, Out-licensed to ophthalmology company Thea

Seb

· CU01 (Diabetic nephropathy), Submitted Phase 3 IND

Jul

· Listed on KOSDAQ (365270)

May
· CU06 (Diabetic Macular Edema), Phase 1 IND approved by FDA (NCT04795037)

· Passed the technical evaluation for Special Technology Assessment Track listing(grade: AA, A)

· CU01 (Diabetic nephropathy), Confirmed safety and efficacy in Phase 2a clinical trial

Jan

· Signed MOU with College of Pharmacy & Institute of Pharmaceutical Science and Technology Research, Korea University

Dec

· Signed research agreement with Severance Hospital: Yonsei University Severance Hospital

Nov

· CU06 U.S. Clinical DP Production Completed (cGMP)

· Signed research agreement with Yonsei University and opened industry-academic cooperation biolab

· Inno-Biz certification (certification number: 200605–01197)

Seb

· Introduction and Transition of Electronic Securities System
· Funding raised (US$ 4 million)

Aug

· Awarded ‘Bio-Tech Science Innovation Award’ from “2020 6th Korea Leading Enterprise Awards”

· CU01 (Diabetic Nephropathy), Completed Test Subject Recruitment for Clinical 2a Phase

· CU03 (Wet AMD), Completed Clinical 2a Phase tolerability Assessment, Recruited additional 60 subjects

· Appointment of stock transfer agent (Korea Securities Depository)

Jun

· Signed research agreement for formulation development with LS Pharma

Apr

· Startups Research Infra Utilization (Research Focused) Grant awarded by the Ministry of SMEs

· CU06, Pharmaceutical Industry Global Advancement Supporting Grant awarded by the Ministry of Health and Welfare

May

· CU06, signed CMO service contract with Yuhan Chemical (South Korea) for cGMP DS production of FDA Phase 1 study

Dec

· CU03 (Wet AMD), Phase 2a IND approved by Ministry of Food and Drug Safety (MFDS)

Nov

· Signed Consultation contract with BL&H (USA) for global BD
· Funding raised (US$ 7.1 million)

Oct

· Relocated headquarters to Pangyo 2nd Techno Valley
· CU06, signed CMO service contract with Patheon (USA) for formulation study & cGMP DP production

Jul

· Samsung Securities selected as underwriter for IPO

Jun

· CU06, Signed CRO service contract with Covance (UK) for global GLP nonclinical study

May

· CU01 (Diabetic Nephropathy), Phase 2a IND approved by Ministry of Food and Drug Safety (MFDS)

Apr

· CU06, Signed Technology transfer agreement of from Yonsei University

Jan

· Relocated R&D center (from Daegu Gyeongbuk Medical Innovation Foundation (DGMIF) to Korea Research Institute of  Chemical Technology (KRICT), Daejeon)

Dec

· Nominated as a membership business of the Korea Research Institute of Chemical Technology (KRICT)

Nov

· Funding raised (US$ 9.0 million)

Oct

· Relocated headquarters (Woorim W-city at Pangyo)

Mar

· CU05 (Lung Cancer), Grant awarded by the Ministry of Science and ICT for the biomedical technology development business project

Jan

· CU02 (NASH & Obesity), Grant awarded by the Ministry of Science and ICT for the biomedical technology development business

Oct

· CU04 (immunotherapy), Grant awarded by Daegu-Gyeongbuk

  Medical Innovation Foundation (DGMIF) New Drug Development

  Center for optimization support

Aug

· CU02 (NASH & Obesity), Signed Technology transfer agreement

  from Gwangju Institute of Science and Technology (GIST),

  Korea Advanced Institute of Science and Technology (KAIST) &

  Kyungpook National University (KNU)

Jun

· CU01, Grant awarded from the Ministry of Trade, Industry and Energy

May

· CU01 Signed research contract with Mcnulty for formulation development

Apr

· CU05, Signed research agreement with College of Pharmacy, Gachon University

Mar

· CU03 (Macular Degeneration), Signed technology transfer

 agreement from Korea Institute of Oriental Medicine (KIOM)

Feb

· CU01 (Renal Fibrosis), Signed technology transfer agreement

  from Kyungpook National University
· CU05 (Lung Cancer), Signed technology transfer agreement

  from Yonsei University

Jan

· Established R&D center at Daegu-Gyeongbuk Medical Innovation

  Foundation (DGMIF) certified as affiliated research institute

Nov

· Registered as a venture business (No. 20160300500)

· Relocated headquarters (Innovalley at Pangyo)

Oct

· Funding raised (US$ 1.5 million)

May

· Established Curacle Co., Ltd. (Gangnam, Seoul)